Goto H, Yuasa K, Sakamaki H, Nakata K, Komuro I, Iguchi M, Okamura T, Ieki R, Tanikawa S, Akiyama H, Onozawa Y, Mochida Y
Department of Internal Medicine, Tokyo Metropolitan Komagome General Hospital, Japan.
Bone Marrow Transplant. 1996 May;17(5):855-60.
To detect cytomegalovirus-associated interstitial pneumonia (CMV-IP) in recipients of BMT in its earliest stage, five CMV methods were assessed for their usefulness using bronchoalveolar lavage fluid as the test specimen. Of the 43 cases enrolled in the study, PCR was positive in 12 cases, shell vial in eight, culture in eight and cytology in three. There were no positive cases in in situ hybridization. Based on this result, the 43 cases were classified into four groups: Group 1, three cases: positive in PCR, shell vial and cytology; Group 2, five cases: positive in PCR and shell vial; Group 3, four cases: positive only in PCR; and Group 4, 31 cases: negative in all CMV tests. Cases in Group 1 were judged as having the highest risk of overt CMV-IP. They were successfully treated with a combination of ganciclovir and immunoglobulin. Group 2 was diagnosed as having active CMV infection and ganciclovir monotherapy was effective for these patients. Groups 3 and 4 were not given anti-CMV therapy, but they were free from CMV-related manifestations throughout the study. The sensitivity and specificity of each survey method for the detection of Groups 1 and 2 were 1.0 and 0.89 in PCR, 1.0 and 1.0 in shell vial, 0.88 and 1.0 in culture, and 0.38 and 1.0 in cytology. Similarly, the positive and negative predictive values were 0.67 and 1.0 in PCR, 1.0 and 1.0 in shell vial, 1.0 and 0.97 in culture, and 1.0 and 0.88 in cytology. Thus, CMV survey on bronchoalveolar fluid was thought to be useful in detecting post BMT CMV-IP in its earliest stage.
为了在骨髓移植(BMT)受者中尽早检测巨细胞病毒相关性间质性肺炎(CMV-IP),使用支气管肺泡灌洗液作为检测标本,对五种CMV检测方法的实用性进行了评估。在纳入研究的43例病例中,PCR检测阳性12例,空斑试验阳性8例,培养阳性8例,细胞学检查阳性3例。原位杂交无阳性病例。根据这一结果,将43例病例分为四组:第1组,3例:PCR、空斑试验和细胞学检查均阳性;第2组,5例:PCR和空斑试验阳性;第3组,4例:仅PCR阳性;第4组,31例:所有CMV检测均为阴性。第1组病例被判定为发生显性CMV-IP的风险最高。他们接受更昔洛韦和免疫球蛋白联合治疗后获得成功。第2组被诊断为有活动性CMV感染,更昔洛韦单药治疗对这些患者有效。第3组和第4组未接受抗CMV治疗,但在整个研究过程中未出现CMV相关表现。各检测方法对第1组和第2组检测的敏感性和特异性分别为:PCR为1.0和0.89,空斑试验为1.0和1.0,培养为0.88和1.0,细胞学检查为0.38和1.0。同样,阳性和阴性预测值分别为:PCR为0.67和1.0,空斑试验为1.0和1.0,培养为1.0和0.97,细胞学检查为1.0和0.88。因此,对支气管肺泡灌洗液进行CMV检测被认为有助于在BMT后尽早检测CMV-IP。